Cytomedix
This article was originally published in The Gray Sheet
Executive Summary
Deerfield, Illinois firm raises $14.7 mil in equity financing from Fusion Capital Fund II. Proceeds will go towards "general corporate purposes, acquisitions and other opportunities," according to a release. Cytomedix' current product offering include the Autologel and ProCuren wound healing agents, composed of naturally occurring growth factors. Applications include treatment of diabetic foot ulcers, venous stasis and pressure ulcers. Separately on April 26, the firm raised $2.1 mil. in convertible bond financing, with a potential of raising up to $6.5 mil. Funds will go towards paying off other debt securities, including bridge financing obtained in connection with the January 2001 purchase of assets from Curative Health Services, maker of the ProCuren product
You may also be interested in...
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.